Trials / Completed
CompletedNCT05751629
Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer
Cohort A: PARP Inhibitor-Naïve Platinum-Resistant Ovarian Cancer Treatment Cohort With TSR-042, Bevacizumab, and Niraparib
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Tesaro, Inc. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this sub study is to evaluate the efficacy of the combination of TSR-042, bevacizumab, and niraparib in participants with advanced, relapsed, high-grade ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 2 prior lines of anticancer therapy, are PARP inhibitor naïve, and have platinum-resistant but not refractory disease. This study is a sub study of the master protocol - OPAL (NCT03574779).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dostarlimab | Dostarlimab was administered. |
| DRUG | Bevacizumab | Bevacizumab was administered. |
| DRUG | Niraparib | Niraparib was administered. |
Timeline
- Start date
- 2018-11-15
- Primary completion
- 2022-04-01
- Completion
- 2022-04-01
- First posted
- 2023-03-02
- Last updated
- 2023-04-21
- Results posted
- 2023-04-21
Locations
10 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05751629. Inclusion in this directory is not an endorsement.